* Syndax Pharmaceuticals Inc SNDX.OQ reported a quarterly
adjusted loss of 80 cents per share for the quarter ended in
June, lower than the same quarter last year, when the company
reported EPS of -64 cents. The mean expectation of
twelve analysts for the quarter was for a loss of 91 cents per
share. Wall Street expected results to range from -97 cents
to -87 cents per share.
* Revenue was $3.50 million; analysts expected zero.
* Syndax Pharmaceuticals Inc's reported EPS for the quarter
was a
loss of 80 cents.
* The company reported a quarterly loss of $68.06 million.
* Syndax Pharmaceuticals Inc shares had risen by 10.6% this
quarter and gained 5.0% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts had risen by
about 11.8%
in the last three months.
* In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.
RECOMMENDATIONS
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 13 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."
* The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"
Wall Street's median 12-month price target for Syndax
Pharmaceuticals Inc is $35.00
This summary was machine generated from LSEG data August 2 at
12:02 a.m. UTC. All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Jun. 30 2024 -0.91 -0.80 Beat
Mar. 31 2024 -0.98 -0.85 Beat
Dec. 31 2023 -0.99 -1.00 Missed
Sep. 30 2023 -0.80 -0.73 Beat